外周 T 细胞淋巴瘤：当前方法的回顾及未来的希望。
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.
机构信息
Medical Oncology, Fox Chase Cancer Center , Philadelphia, PA , USA.
出版信息
Front Oncol. 2013 May 28;3:138. doi: 10.3389/fonc.2013.00138. eCollection 2013.
Abstract
Peripheral T-cell lymphomas (PTCL) are a diverse group of lymphoproliferative disorders, which share a common denominator of overall poor prognosis, with few exceptions. In this article, the authors review current standard of care approaches for the treatment of PTCLs, the role of stem-cell/bone marrow transplantation, and current developments in novel targeted therapies.
摘要
外周 T 细胞淋巴瘤（PTCL）是一组异质性的淋巴增殖性疾病，除了少数例外，它们的总体预后都很差。本文作者回顾了目前 PTCL 治疗的标准护理方法、干细胞/骨髓移植的作用，以及新型靶向治疗的最新进展。
相似文献
1
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.外周 T 细胞淋巴瘤：当前方法的回顾及未来的希望。
Front Oncol. 2013 May 28;3:138. doi: 10.3389/fonc.2013.00138. eCollection 2013.
2
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.复发/难治性T细胞淋巴瘤当前及未来治疗的全景临床综述：外周T细胞淋巴瘤
Crit Rev Oncol Hematol. 2016 Mar;99:214-27. doi: 10.1016/j.critrevonc.2015.12.016. Epub 2016 Jan 3.
3
Novel therapies for peripheral T-cell lymphomas.外周 T 细胞淋巴瘤的新型治疗方法。
Ther Adv Hematol. 2013 Jun;4(3):173-87. doi: 10.1177/2040620713481980.
4
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.复发或难治性外周 T 细胞淋巴瘤的治疗选择。
Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24.
5
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?外周 T 细胞淋巴瘤的治疗：我们是数据驱动还是在驱动数据？
Curr Treat Options Oncol. 2013 Jun;14(2):212-23. doi: 10.1007/s11864-013-0232-x.
6
Chemotherapeutic advancements in peripheral T-cell lymphoma.外周 T 细胞淋巴瘤的化疗进展。
Semin Hematol. 2014 Jan;51(1):17-24. doi: 10.1053/j.seminhematol.2013.11.006. Epub 2013 Nov 14.
7
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.外周 T 细胞淋巴瘤中的造血细胞移植和过继细胞治疗。
Curr Hematol Malig Rep. 2020 Aug;15(4):316-332. doi: 10.1007/s11899-020-00590-5.
8
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.一项罗米地辛联合培美曲塞治疗复发难治性 T 细胞淋巴瘤的 I 期临床研究显示出显著的疗效。
Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15.
9
New drug therapies in peripheral T-cell lymphoma.外周 T 细胞淋巴瘤的新型药物治疗。
Expert Rev Anticancer Ther. 2011 Mar;11(3):457-72. doi: 10.1586/era.11.4.
10
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.罗米地辛用于治疗外周T细胞淋巴瘤。
Oncologist. 2015 Sep;20(9):1084-91. doi: 10.1634/theoncologist.2015-0043. Epub 2015 Jun 22.
引用本文的文献
1
Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.造血系统癌症中致癌性 STAT3 和 STAT5 信号通路的药理学抑制作用
Cancers (Basel). 2020 Jan 18;12(1):240. doi: 10.3390/cancers12010240.
2
F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma.间变大细胞淋巴瘤（一种罕见的淋巴瘤亚型）的 F-FDG PET/CT 影像学表现。
Cancer Imaging. 2020 Jan 10;20(1):4. doi: 10.1186/s40644-019-0278-5.
3
Refractory Septic Shock due to Underlying Immunocompromised Disease: A Case of Fatal Peripheral T-Cell Lymphoma Not Otherwise Specified in a Young Hispanic Woman.潜在免疫功能低下疾病导致的难治性感染性休克：一名年轻西班牙裔女性的致命性未另行指定的外周T细胞淋巴瘤病例
Case Rep Oncol. 2018 Jun 22;11(2):404-411. doi: 10.1159/000488312. eCollection 2018 May-Aug.
4
STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.信号转导和转录激活因子5（STAT5）抑制可诱导外周T细胞淋巴瘤中肿瘤坏死因子相关凋亡诱导配体（TRAIL）/死亡受体4（DR4）依赖性凋亡。
Oncotarget. 2018 Mar 30;9(24):16792-16806. doi: 10.18632/oncotarget.24698.
5
Early diagnosis of an isolated primary peripheral T-cell lymphoma masquerading as massive gingival enlargement in a pediatric patient.一名儿科患者伪装成牙龈大量肿大的孤立性原发性外周T细胞淋巴瘤的早期诊断。
J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):421-424. doi: 10.4103/jomfp.JOMFP_73_15.
6
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.贝利司他用于复发或难治性外周T细胞淋巴瘤
J Adv Pract Oncol. 2016 Mar;7(2):209-218. doi: 10.6004/jadpro.2016.7.2.6. Epub 2016 Mar 1.
7
Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.外周T细胞淋巴瘤中ATM与常见γ链信号相关基因的并发突变
PLoS One. 2015 Nov 4;10(11):e0141906. doi: 10.1371/journal.pone.0141906. eCollection 2015.
8
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.利用 CD4 特异性嵌合抗原受体 (CAR) 工程化 T 细胞对人 T 细胞恶性肿瘤进行临床前靶向治疗。
Leukemia. 2016 Mar;30(3):701-7. doi: 10.1038/leu.2015.311. Epub 2015 Nov 3.
9
Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.靶点、毒素与T细胞——外周T细胞淋巴瘤治疗中新单克隆抗体的综述
Curr Hematol Malig Rep. 2015 Dec;10(4):438-47. doi: 10.1007/s11899-015-0290-1.
10
Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.使用莫格利珠单抗进行自体干细胞移植后，急性白血病期CCR4阳性γδ外周T细胞淋巴瘤持续完全缓解
Int J Hematol. 2015 Oct;102(4):498-505. doi: 10.1007/s12185-015-1805-1. Epub 2015 May 15.
本文引用的文献
1
Differential expression of aurora-A kinase in T-cell lymphomas.Aurora-A 激酶在 T 细胞淋巴瘤中的差异表达。
Mod Pathol. 2013 May;26(5):640-7. doi: 10.1038/modpathol.2012.211. Epub 2013 Feb 15.
2
Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution.外周 T 细胞淋巴瘤：单一机构 208 例病例的组织学、分期和治疗反应分析。
Leuk Lymphoma. 2013 Nov;54(11):2392-8. doi: 10.3109/10428194.2013.776680. Epub 2013 Mar 27.
3
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.亲缘供者 HLA 完全相合或单倍体相合异基因外周血或骨髓移植治疗外周 T 细胞淋巴瘤的结果。
Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6. doi: 10.1016/j.bbmt.2013.01.006. Epub 2013 Jan 29.
4
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.一项多中心 II 期临床试验，旨在确定联用替伊莫单抗和环磷酰胺、多柔比星、长春新碱和泼尼松治疗未经治疗的外周 T 细胞淋巴瘤的安全性和疗效：CONCEPT 研究。
Leuk Lymphoma. 2013 Jul;54(7):1373-9. doi: 10.3109/10428194.2012.742521. Epub 2013 Jan 29.
5
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.alisertib（MLN8237）是一种研究性药物，可抑制 Aurora A 和 B 的活性，抑制增殖，促进内复制，并诱导 T-NHL 细胞系凋亡，这支持其在 PTCL 治疗中的重要性。
Leuk Res. 2013 Apr;37(4):434-9. doi: 10.1016/j.leukres.2012.10.017. Epub 2012 Nov 12.
6
Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.一项关于难治性或复发性 T 细胞淋巴瘤中苯达莫司汀的前瞻性、开放标签、II 期试验结果：BENTLY 试验。
J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.
7
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.多中心 II 期临床试验研究普乐沙福治疗复发/难治性非霍奇金淋巴瘤。
Haematologica. 2013 Mar;98(3):357-63. doi: 10.3324/haematol.2012.069757. Epub 2012 Oct 12.
8
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. upfront 自体干细胞移植在外周 T 细胞淋巴瘤中的应用：NLG-T-01
J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30.
9
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.硼替佐米联合 CHOP 方案作为 III/IV 期外周 T 细胞淋巴瘤患者的一线治疗：一项多中心、单臂、Ⅱ期临床试验。
Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.
10
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
Zotero 插件